Amgen Inc at Guggenheim Partners Healthcare Talks Oncology Days Transcript

Feb 12, 2021 / 05:30PM GMT
Michael Werner Schmidt - Guggenheim Securities, LLC, Research Division - Senior Analyst & Senior MD

All right. Hello. I'm Michael Schmidt, senior biotech analyst with Guggenheim Securities, and it's my great pleasure to welcome Amgen to this year's Virtual Guggenheim Oncology Day.

With us today, we have Gregory Friberg, who is the Vice President of Global Development at Amgen; as well as Arvind Sood, who most of you know, who's heading up Investor Relations at Amgen. Welcome, guys, and thanks so much for joining us this year.

Gregory Friberg - Amgen Inc. - Head of Oncology Global Development

Thanks, Michael.

Arvind Sood - Amgen Inc. - VP of IR

Thank you, Michael.

Questions and Answers:

Michael Werner Schmidt - Guggenheim Securities, LLC, Research Division - Senior Analyst & Senior MD

I thought, in the interest of time, I will jump right into Q&A. Maybe a bigger picture question upfront. Oncology is obviously one of the biggest and fastest-growing
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot